Long‐term biological variability and the generation of a new reference interval for plasma N‐terminal pro‐B‐type natriuretic peptide in Labrador retrievers by Gomart, S et al.
Journal of Small Animal Practice  •  © 2020 The Authors Journal of Small Animal Practice published by John Wiley & Sons Ltd on behalf of 1 
British Small Animal Veterinary Association 
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work 
is properly cited.
PAPER
Long-term biological variability and the 
generation of a new reference interval 
for plasma N-terminal pro-B-type 
natriuretic peptide in Labrador 
retrievers
S. Gomart1,*, D. Allaway†, M. Harrison†, D. Dickson‡, J. Seo §, L. Ferasin¶, J. R. Payne *,  
M. J. Hezzell || and K. Borgeat *
*Langford Vets, University of Bristol, Bristol, UK
†MARS PetCare Ltd, Waltham Centre for Pet Nutrition, Waltham, UK
‡HeartVets, Porthcawl, CF11 8DG, UK
§Royal Veterinary College, London, AL9 7TA, UK
¶Lumbry Park Veterinary Specialists, Alton, GU34 3HL, UK
||Bristol Veterinary School, University of Bristol, Bristol, UK
Corresponding author email: samantha.gomart@bristol.ac.uk
Objectives: First, to investigate the biological variability of N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) in healthy Labrador retrievers and compare this with current laboratory recommendations 
for dilated cardiomyopathy screening. Second, to calculate a breed-specific reference interval and 
validate it in a retrospective cohort.
Materials and MethOds: Plasma NT-proBNP was measured in 51 clinically healthy Labrador retrievers at 
0, 2, 4, 6 and 8 weeks. Coefficient of variation for individual dogs over time, the coefficient of variation 
for the group at each time point and the index of individuality were calculated. A reference interval 
was derived and tested on a clinical dataset available from four UK cardiology referral centres.
results: Median NT-proBNP was 865 pmol/L (315 to 2064 pmol/L). Mean individual coefficient of 
variation was 19% (95% CI: 16 to 21%) and group coefficient of variation was 43% (95% CI: 41 to 
46%), with index of individuality at 0.44. The breed-specific reference interval was 275 to 
2100 pmol/L. In the validation group, 93% of NT-proBNP measurements from healthy dogs were within 
the reference interval. NT-proBNP measurements exceeded the reference interval in 82% of dogs with 
dilated cardiomyopathy. The upper bound of the reference interval (2100 pmol/L) had a positive predic-
tive value of 90% and a negative predictive value of 87% for identification of dilated cardiomyopathy in 
this population.
clinical significance: Breed-specific reference intervals might improve the diagnostic accuracy of 
NT-proBNP measurement. Applying the currently recommended general cut-off value to Labradors is 
likely to result in frequent false positives and diagnosis would be improved by application of the new 
breed-specific reference interval calculated here.
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INTRODUCTION
N-terminal pro-hormone of B-type natriuretic peptide (NT-
proBNP) is released by the atrial and ventricular myocardium as 
a result of increased stretch or stress on the heart. Plasma NT-
proBNP is higher in dogs with heart failure, as well as in dogs 
with occult heart disease (Prosek et al. 2007, Boswood et al. 2008, 
Fox et al. 2009, Singletary et al. 2012). Occult dilated cardiomy-
opathy (DCM) can be difficult to detect without echocardiogra-
phy, as only an estimated 33% of affected dogs have an audible 
heart murmur (Martin et al. 2009). Given the previously iden-
tified benefit of pimobendan in Doberman pinschers with pre-
clinical DCM (Summerfield et al. 2012), many veterinarians wish 
to detect occult disease in at-risk individuals. Rather than perform 
echocardiography in every at-risk dog, screening using plasma NT-
proBNP measurement is an attractive proposition for veterinarians 
in general practice. Based on a study evaluating NT-proBNP in 
Doberman pinschers with occult DCM (Wess et al. 2011) labora-
tory advice suggests that, in an at-risk breed of dog, plasma NT-
proBNP ≥900 pmol/L is compatible with clinically meaningful 
heart disease (IDEXX Laboratories interpretative criteria; https://
idexxcom-live-b02da1e51e754c9cb292133b-9c56c33.aldryn-
media.com/filer_public/26/89/26893bee-e598-479f-ba85-
b0084b2ff542/cardiopet-interpretive-criteria-canine.pdf, accessed 
August 23, 2018), but was based on a previous-generation assay.
Despite its potential utility for screening purposes, NT-
proBNP is subject to day-to-day variability, which could 
potentially generate false-positive and false-negative test results 
in patients in which measurements are close to the diagnostic 
cut-off. Previous studies investigating the biological variability 
of NT-proBNP have suggested approximately 50% variabil-
ity over a 6 to 7-week period (Ruaux et al. 2015, Winter et al. 
2017). However, these data were obtained from relatively small 
samples containing a mixture of dog breeds, variable environ-
ments and inconsistent sample handling. Additionally, breed dif-
ferences in plasma NT-proBNP have been identified in healthy 
dogs (Sjöstrand et al. 2014). Some breeds, including the Labra-
dor retriever, were reported to have median NT-proBNP values 
which exceeded 900 pmol/L (Sjöstrand et al. 2014). Both bio-
logical variability and breed differences suggest that the results 
of NT-proBNP screening for occult DCM in non-Doberman 
breeds should be interpreted with caution.
The Labrador retriever is considered predisposed to DCM 
(Martin et al. 2009) and is a common breed in the UK; in 
2017, it was the most frequently registered breed of dog with 
the Kennel Club (IDEXX Laboratories interpretative criteria; 
https://idexxcom-live-b02da1e51e754c9cb292133b-9c56c33.
aldryn-media.com/filer_public/26/89/26893bee-e598-479f-
ba85-b0084b2ff542/cardiopet-interpretive-criteria-canine.pdf, 
accessed August 23, 2018). It is therefore reasonable to assume 
that UK-based practitioners might use plasma NT-proBNP 
measurement as a screening test for occult DCM. Thus, a better 
understanding of biological variability and a breed-specific refer-
ence interval for Labradors is likely to be clinically useful.
The aim of this study was to assess the biological variation in 
plasma NT-proBNP over 32 weeks in a large cohort of clinically 
healthy, echocardiographically normal Labrador retrievers, for 
which the environment and exercise regime were standardised. 
In addition, we aimed to derive and test a novel, breed-specific 
reference interval for plasma NT-proBNP in Labradors.
Our hypotheses were: (1) the mean plasma NT-proBNP 
in clinically healthy Labradors exceeds 900 pmol/L, (2) serial 
measurement of plasma NT-proBNP in Labradors will reveal 
clinically-relevant biological variability over 32 weeks, and (3) a 
newly-derived reference interval from this population of healthy 
Labradors more accurately identifies dogs with occult DCM than 
a cut-off value of 900 pmol/L.
MATERIALS AND METHODS
Evaluation of biological variability and reference 
interval
The study protocol was approved by the Waltham Animal Wel-
fare and Ethical Review Board, and carried out under the author-
ity of the Animals (Scientific Procedures) Act 1986.
Healthy adult Labrador retrievers (n = 51), fed nutrition-
ally complete diets (Allaway et al. 2017, Harrison et al. 2017), 
were housed at the Waltham Centre for Pet Nutrition, UK. The 
environment and exercise regime were standardised for all dogs. 
Prior to enrolment, dogs were habituated to all study procedures, 
including echocardiography and blood sampling. At enrolment, 
all dogs underwent complete physical examination, 2-dimen-
sional and Doppler echocardiography, complete blood count and 
serum biochemical profile. Dogs were eligible to proceed with 
the study protocol if considered clinically healthy (no evidence of 
cardiac or systemic disease detected on the aforementioned tests).
All echocardiographic examinations were carried out by a 
board-certified veterinary cardiologist (KB) using a cardio-
vascular ultrasound platform (GE Vivid I, with a 5S phased-
array transducer; GE Healthcare, Hatfield, UK). Transthoracic 
2-dimensional and Doppler echocardiographic studies were 
performed from both sides of the thorax, alongside a simultane-
ous electrocardiogram (ECG) recording. Dogs were considered 
echocardiographically normal if they met all of the following 
criteria: left atrial-to-aortic root ratio (LA:Ao) <1.5 measured in 
the right parasternal short-axis window, optimised for the heart 
base; left ventricular end-systolic volume indexed to body surface 
area (ESVi; measured from a right parasternal long-axis window) 
<30 mL/m2; ejection fraction (EF) >45%; left ventricular inter-
nal diameter in diastole normalised for body weight (LVIDd-N, 
measured using M-mode cursor bisecting the left ventricle in a 
right parasternal short-axis window optimised for the papillary 
muscles and chordae tendineae) <1.7 and diastolic left ventricu-
lar wall thickness were within reference intervals for body weight 
using an allometric scaling method (Cornell et al. 2004). Aor-
tic and pulmonic Doppler flow profiles were obtained and con-
sidered normal if aortic maximum velocity was <1.7 m/second 
(from a subcostal view) and pulmonic maximum velocity was 
<1.2 m/second (from the right parasternal short-axis window).
Fasted blood samples were collected from the jugular vein into 
EDTA containers. Samples were obtained at weeks 0, 8, 16, 24 and 
NT-proBNP in Labrador retrievers
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32. Sampling was performed at the same time of day (within a 2-hour 
window) and EDTA samples were centrifuged (1000 g, 10 minutes, 
4°C) to separate plasma. All plasma samples (500 μL) were prepared 
within 1 hour of blood collection and stored in polypropylene tubes 
at −80°C. After shipping on dry ice to a reference laboratory (IDEXX 
Laboratories, Wetherby, UK), batch analysis of NT-proBNP was per-
formed in duplicate with the second-generation canine Cardiopet® 
proBNP ELISA (detection limits 16 to 10,000 pmol/L).
Validation of the newly derived reference interval
Clinical records of four cardiology referral centres in the UK 
(Langford Vets, Royal Veterinary College, Heart Vets and Lumbry 
Park Veterinary Specialists) were retrospectively searched for cli-
ent-owned Labradors with results of echocardiography and plasma 
NT-proBNP measurement available. Dogs were classified accord-
ing to the diagnosis made by a cardiology diplomate as appar-
ently healthy (no heart disease nor significant systemic disease), or 
as having cardiac disease. Within the cardiac disease group, dogs 
were additionally sub-classified as having been diagnosed with 
DCM or other cardiac diseases. Other data collected were plasma 
NT-proBNP concentration, echocardiographic diagnosis, age, sex, 
neutering status and bodyweight. NT-proBNP concentrations 
were compared between groups and with the prospectively derived 
reference interval to evaluate potential clinical utility.
Statistical analysis
Statistical analysis was performed using commercially available 
software (SPSS 22 for Windows, IBM GraphPad Prism Graph-
Pad Software, La Jolla, California). Data were assessed for nor-
mality both graphically and using Shapiro Wilk tests. Descriptive 
statistics were reported as mean (±standard deviation) for nor-
mally distributed data and as the median (range) for non-nor-
mally distributed data. Outliers were determined using the Tukey 
Method: defining limits on the sample values that were a factor 
1.5 of the interquartile range below the 25th or above the 75th 
percentile. Statistical significance for all tests was set at P < 0.05. 
The maximum, minimum and mean NT-proBNP values and 
measures of variability were calculated.
Variability for plasma NT-proBNP values was assessed by cal-
culating the group coefficient of variation (CVG; corresponding to 
the variability between dogs at each time-point) and the individ-
ual coefficient of variation (CVI; corresponding to the variability 
within each dog over all time-points). The CVI was calculated 
using the square root of the variance (standard deviation) of indi-
vidual dog over all time points, divided by the mean value of 
individual dog over all time points. The result was reported as the 
mean CVI for all dogs. The CVG was calculated using the square 
root of the variance of all dogs at a single time point, divided by 
the mean value of all dogs at a single time point. This was done 
at the first visit, at 2, 4, 6 and 8 months. The result was reported 
as the mean CVG for all time-points. The index of individual-
ity (IOI) was calculated as the CVI: CVG ratio (Fraser & Har-
ris 1989, Fraser 2001). For derivation of the reference interval, 
a single sample was randomly selected from each dog using an 
online random number generator (random.org). The reference 
interval calculation was subsequently determined using a robust 
bi-weight quantile method computed on the reflected sample 
(Analyse-it Software, Ltd).
Using retrospective clinical data, positive and negative pre-
dictive values (PPV and NPV, respectively) for the detection of 
DCM were calculated using the upper bound of the derived ref-
erence interval. PPV was determined as the ratio between true 
positives and the total number of positives, whereas the NPV 
was determined as the ratio between true negatives and the total 
number of negatives. An online statistics calculator (The Chinese 
University of Hong Kong, https://www2.ccrb.cuhk.edu.hk/stat/
confidence%20interval/Diagnostic%20Statistic.htm#Help) was 
used to formulate 95% confidence intervals (95% CI) for PPV 
and NPV, because of the relatively small validation cohort.
RESULTS
Biological variability of NT-proBNP and derivation 
of a breed-specific reference interval
A group of 62 Labradors underwent echocardiography training 
over a 2-month period, which involved them presenting them-
selves and lying in right and left lateral recumbency for echocar-
diography with minimal restraint. All dogs successfully completed 
this training, but 10 dogs were excluded from the study because 
behavioural assessment indicated that the dogs could not undergo 
blood sampling without undue stress. Serial measurement of NT-
proBNP was performed in 52 dogs. Analysis identified one dog 
as an outlier, which was removed from the statistical analysis. Of 
the 51 dogs analysed, median age was 5.2 years (2.3 to 8.2 years). 
More female dogs (n = 32) were recruited than males (n = 19). All 
animals were neutered. The median weight was 26.6 kg (23.5 to 
29.7 kg). One other dog was removed from the variability analy-
sis because only one sample was collected. Data from 50 dogs 
were included in the analysis of biological variability.
A total of 242 plasma samples were obtained. All five planned 
plasma samples were collected from 44 dogs, four of five were 
collected in four dogs, and in one dog each, three, two and one 
FIG 1. Serial measurements of plasma N-terminal pro-B-type natriuretic 
peptide (NT-proBNP) over a 32 week period in 51 healthy Labrador 
retrievers. Each solid line represents an individual dog. The dotted 
line represents the laboratory recommended cut-off for dilated 
cardiomyopathy (DCM) screening at 900 pmol/L
S. Gomart et al.
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Table 1. Cardiac diagnoses of Labrador retrievers included 
in the retrospective validation dataset
Diagnosis Number of dogs
No cardiac abnormalities detected 
(apparently healthy)
14
Dilated cardiomyopathy 11
Isolated arrhythmia
Third degree atrioventricular block 3
Isorhythmic atrioventricular dissociation 1
Infiltration or inflammation 2
Mitral valve disease 1
Pericarditis 1
Tricuspid valve dysplasia 1
sample only were collected. Median NT-proBNP was 865 pmol/L 
(315 to 2064 pmol/L). In healthy Labradors, 38.8% (94/242) of 
plasma samples obtained over the 32-week study period exceeded 
900 pmol/L. At least one NT-proBNP measurement >900 pmol/L 
was recorded in 64.7% of dogs during the study period (Fig 1). 
The calculated CVI was 19% (95% CI: 17 to 22), and CVG was 
43% (95% CI: 41 to 46%). IOI was 0.44. The reference interval 
derived from this group of healthy Labrador retrievers was 275 to 
2100 pmol/L (95% CI for lower value 120 to 341, for upper value 
1782 to 2376) (Fig 2).
Validation of the breed-specific reference interval
Clinical record searches from the four referral centres identified 
34 suitable case records. Cardiac disease was diagnosed by a cardi-
ologist in 20 dogs, with 14 dogs having no evidence of heart dis-
ease (Table 1). Population characteristics are presented in Table 2.
In the normal group, median plasma NT-proBNP was 
1238 pmol/L (760 to 2307 pmol/L) and 13/14 (93%) of 
results were within the breed-specific reference interval. In 
dogs with any cardiac disease, median plasma NT-proBNP was 
2927 pmol/L (449 to 10,000 pmol/L) and 14/20 (73%) of mea-
surements were >2100 pmol/L. In the sub-group of Labradors 
with DCM, median plasma NT-proBNP was 2934 pmol/L 
(1716 to 10,000 pmol/L) and 9/11 (82%) of measurements were 
>2100 pmol/L (Fig 3).
Considering only dogs with DCM versus normal dogs, using 
the laboratory recommended cut-off value of >900 pmol/L 
yielded a PPV of 46% (95% CI: 26 to 66) and NPV of 100% 
(95% CI: 100 to 100) for identification of DCM. Using the 
upper bound of the new breed-specific reference interval as a 
cut-off (>2100 pmol/L) yielded a PPV of 90% (95% CI: 71 to 
100) and an NPV of 87% (95% CI: 69 to 100) for identification 
of DCM.
DISCUSSION
The results of this study suggest that the laboratory recommended 
cut-off for NT-proBNP of 900 pmol/L for DCM screening in 
Labrador retrievers results in unacceptably low diagnostic accu-
racy and a Labrador-specific reference interval should be adopted. 
Not only do apparently healthy Labradors appear to have a higher 
plasma NT-proBNP than other breeds, as described previously 
(Sjöstrand et al. 2014), but they exhibit clinically important long-
term biological variability. Whilst a relatively low cut-off value will 
strengthen the negative predictive value, frequent false-positive 
results may be unacceptable in a practical screening programme 
FIG 2. Mean and range plots displaying the degree of biological variability of plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) 
measurements in healthy Labradors over 32 weeks, and the reference interval derived from these data. The calculated reference interval was 275 to 
2100 pmol/L. The laboratory recommended upper reference limit of 900 pmol/L is illustrated by a vertical dashed line
NT-proBNP in Labrador retrievers
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for animals with no current clinical signs of disease. We therefore 
suggest that a new reference interval of 275 to 2100 pmol/L is 
used by practitioners aiming to identify which Labradors should 
undergo echocardiography for DCM screening.
In our cohort of clinically healthy Labradors, we identified a 
high degree of biological variability in plasma NT-proBNP mea-
surements. The CVI (within subject biological variability over time) 
was 19% and the CVG (biological variability within the group at 
each time point) was 43%. This degree of variability is in agree-
ment with previous studies reported from cohorts of dogs made up 
of a mixture of breeds (Ruaux et al. 2015, Winter et al. 2017), but 
our study featured a larger sample size over a longer time frame, 
and a homogeneous population of dogs: same breed, uniform diet, 
environment and exercise regime, fed to maintain an ideal body 
condition score and a standardised sampling time within the day. 
This excludes some of the innate variation in plasma NT-proBNP 
measurements between breeds (Sjöstrand et al. 2014), different 
sampling times (diurnal variation) (Goetze et al. 2010) and dif-
ferences in exercise regimens (Hunt et al. 2018, Park et al. 2018).
The IOI arising from this study was low, at 0.44. This is in 
accordance with a previous report of low IOI for plasma NT-
proBNP measurements (Winter et al. 2017). In tests with low 
IOI (<0.6), there is low individual variability relative to group 
variability (in the present study, 19% versus 43%). In this situ-
ation, clinically meaningful changes in an individual over time 
may be masked by group variation. However, animals with values 
above the upper bound of the reference interval are likely to be 
truly abnormal (Fraser 2001). This is supported by a strong PPV 
of 90% for DCM screening in our validation cohort. However, it 
is worth considering that some dogs within the population may 
be abnormal at a lower plasma NT-proBNP; this is supported 
by the data having a low IOI. In tests exhibiting this, an upward 
trend over time may suggest that an individual is developing an 
abnormality despite being within the overall population refer-
ence interval (Fraser 2001). Therefore, in a Labrador for which 
clinicians have a high index of suspicion for cardiac disease (for 
instance, a close family history), an upward trend over time (we 
suggest three consecutive samples over 1 to 2 months, given the 
degree of variability in our data) might suggest that echocardiog-
raphy is indicated, even if NT-proBNP measurements remain 
within the reference interval.
Our study is subject to several limitations. First, circulating 
plasma NT-proBNP concentrations can be affected by, amongst 
other things, azotaemia, pulmonary hypertension, sepsis, or 
systemic hypertension (Oyama et al. 2013). Whilst we did our 
best to exclude dogs possibly affected by these conditions from 
both data sets, it is possible that affected dogs were inadvertently 
included. Secondly, the derivation and validation populations of 
dogs in this study were not identical, with the validation cohort 
including some older dogs that might be more likely to have 
comorbidities. In humans, an association of increasing age with 
the inability to lower NT-proBNP has been shown (Richards 
2016). This relationship appears to reflect the interaction of age 
with the total burden of comorbidities rather than reflecting an 
intrinsic characteristic of age per se (Richards 2016). Also, in the 
validation cohort, samples may have been handled differently 
(albeit all submitted to the same laboratory), and the popula-
tion would have been less homogeneous than the group of dogs 
used to derive the reference interval. Some may also have been in 
congestive heart failure at the time of NT-proBNP measurement, 
which would not reflect the use of the test by a practitioner as a 
screening tool in an apparently healthy dog. There were also only 
a relatively small number of cases available for inclusion. Whilst 
the heterogeneity more accurately represents client-owned dogs 
presenting to clinical practice, this and the small sample size 
might have influenced the calculated PPV and NPV. In addition, 
all dogs were referred to cardiologists, so might not represent the 
wider general practice population of dogs. Also, in the derivation 
cohort of apparently healthy dogs, individuals underwent echo-
cardiography at baseline only. Although an ECG was recorded 
Table 2. Population characteristics of client-owned Labradors in the validation cohort
Group n Weight (kg), median (range) Age (years), median (range) Male Plasma NT-proBNP (pmol/L),  
median (range)
Normal 14 30.9 (24.7 to 41) 8 (2 to 13) 7/14 1238.5 (760 to 2307)
All cardiac disease 20 30.5 (26.2 to 48.7) 7.5 (1 to 13) 16/19 2927 (449 to 10,000)
DCM 11 30 (26.6 to 48) 7.5 (1 to 13) 8/11 2934 (1716 to 10,000)
DCM Dilated cardiomyopathy, NT-proBNP N-terminal pro-B-type natriuretic peptide.
FIG 3. Compound dot plots displaying plasma N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) measurements in dogs with normal 
cardiac examinations (apparently healthy, n = 14) and dogs with 
dilated cardiomyopathy (n = 11). The upper limit of a proposed breed-
specific reference interval is illustrated by the horizontal dashed line 
(2100 pmol/L)
S. Gomart et al.
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during the echocardiogram and showed normal sinus rhythm for 
all the dogs, a Holter (24 hours ECG) would have been neces-
sary to further confirm the absence of some arrhythmias over a 
longer time period. It is therefore possible that some dogs might 
have developed undetected cardiac disease over the 32 week-long 
study period, or have suffered unacknowledged cardiac arrhyth-
mias. Although unlikely, this would have skewed our assessment 
of biological variability. It is worth considering that in Doberman 
pinschers with various stages of DCM, diagnosed based on echo-
cardiographic and 24 h Holter ECG data, no significant differ-
ence in NT-proBNP was identified between unaffected dogs and 
those with a diagnosis based on Holter only (i.e. normal echocar-
diogram) (Wess et al. 2011). Therefore, our proposed reference 
interval should be considered as an additional screening tool for 
dogs with DCM detectable on imaging, and may miss those with 
arrhythmias only. Finally, the apparently healthy dogs were all 
kept in a controlled kennel environment that may not be entirely 
representative of a client-owned dog population.
In conclusion, clinically important biological variability of 
plasma NT-proBNP was identified over 32 weeks in a relatively 
homogeneous group of Labrador retrievers, which frequently 
would lead to a false-positive result in DCM screening using a cut-
off of 900 pmol/L. For this reason, we recommend a new, breed-
specific, upper bound of 2100 pmol/L. Further investigation for 
heart disease should be recommended in Labrador retriever in 
which plasma NT-proBNP measurement exceeds 2100 pmol/L. 
Trends over time should be monitored in high-risk individual dogs.
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